PrEP is an effective means of prevention of HIV infection but not used by high risk individuals, especially those who use substances, in all regions. Similarly, effective approaches to opioid use, especially Medication Assisted Treatment, medication to reverse overdose, and counseling, are not used universally by those in need.
This study will obtain data essential for implementation of PrEP services and Opioid Use services to higher risk people who use drugs (PWUD), especially (1) men who have sex with men (MSM) who use stimulants and club drugs and (2) PWUD who use opioids, in STI clinics and community-based organizations (CBOs), in eight Southern cities with highest HIV incidence. This study will be a single-assessment, multi-level [agency director (N=16), provider (N=≤320), (stimulant/club drug-using MSM and opiate-using) consumer (N=480)] implementation survey study.
Primary and secondary outcome data will describe extent of and nature of knowledge of, interest in, perceived barriers and facilitators to, and suggested strategies for implementing PrEP-related and opioid use-related services in these three major types of stakeholders. Opioid use-related services will include a) medication assisted treatment (MAT) for opioid use disorder (OUD); b) psychosocial counseling; c) opioid overdose prevention services; and d) syringe services. Exploratory analyses will use the iPARIHS (Integrated Promoting Action on Research Implementation In Health Services) framework to examine predictors for knowledge, experience and willingness, to use or link to pre-exposure prophylaxis (PrEP) and opioid use-related services. Structural-, provider- and consumer-level predictors will be analyzed to inform readiness for PrEP and opioid-use services.
- CTN-0082-A-1: Covid-19 Vaccine Readiness in People Who Use Substances In Community STI Clinics and Substance Use Intervention or Harm Reduction Programs In Eight Higher HIV Incidence Southeastern Cities
All Participating Nodes: